ALTERITY THERAPEUTICS

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

10 Apr 2025 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

03 Apr 2025 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

27 Mar 2025 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Raises A$40.0 million in Placement

10 Feb 2025 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

30 Jan 2025 07:35:00 By Nasdaq GlobeNewswire

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

24 Jan 2025 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

09 Jan 2025 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

04 Dec 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

19 Nov 2024 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

12 Nov 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

06 Nov 2024 07:35:00 By Nasdaq GlobeNewswire

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

31 Oct 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

14 Oct 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

11 Oct 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

02 Oct 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

30 Sep 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®

23 Sep 2024 07:35:00 By Nasdaq GlobeNewswire

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

31 Jul 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Present at MST Financial Webinar

24 Jul 2024 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

17 Jul 2024 07:35:00 By Nasdaq GlobeNewswire